Information on the target
Clinical Best Solutions (CBS) is a prominent Contract Research Organization (CRO) based in Poland, specializing in conducting Phase II-IV clinical studies across a diverse range of therapeutic areas. These areas include cardiology, neurology, oncology, psychiatry, and diabetology, positioning CBS as a key player in the biopharmaceutical landscape. The acquisition of CBS by Penta Hospitals Badania Kliniczne marks a strategic expansion of Penta's capabilities in clinical research, enhancing its service offerings and operational reach within the healthcare sector.
With this acquisition, Penta Hospitals Badania Kliniczne will increase its network of research centers in Poland to a total of 11, thereby strengthening its position in the biopharmaceutical industry. This integration is expected to facilitate more comprehensive clinical trials and improve patient access to cutting-edge therapies, ultimately contributing to advancements in medical research and patient care.
Industry overview in the target’s specific country
The biopharmaceuticals industry in Poland has experienced significant growth over the past decade, driven by an increasing demand for innovative therapies and a robust regulatory framework that supports clinical research. Poland has emerged as a favorable destination for biopharmaceutical companies due to its well-educated workforce, competitive costs, and a growing number of clinical trial sites. The country has also seen a rise in investment from both domestic and international players, further bolstering its position in the global biopharmaceutical market.
Poland's biopharmaceutical sector benefits from a strong emphasis on research and development, supported by various government initiatives aimed at fostering innovation. The Polish government has implemented policies to streamline the approval process for clinical trials, making it easier for companies to conduct research and bring new drugs to market. This supportive environment has attracted numerous CROs and pharmaceutical companies to establish operations in the country, contributing to a vibrant ecosystem for biopharmaceutical development.
Moreover, the increasing prevalence of chronic diseases and an aging population are driving the demand for new therapies, creating opportunities for biopharmaceutical companies to address unmet medical needs. The collaboration between academic institutions and industry players is also on the rise, facilitating knowledge transfer and accelerating the development of novel treatments. As a result, Poland is poised to become a key player in the European biopharmaceutical landscape, with a growing number of clinical trials and research initiatives taking place across the country.
The rationale behind the deal The acquisition of Clinical Best Solutions by Penta Hospitals Badania Kliniczne is strategically aligned with Penta's goal of enhancing its clinical research capabilities and expanding its footprint in the bi…